RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 51st Annual Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) in Chicago, Illinois.
